Home › Orexigen: Contrave Sales Dip, Passing Belviq Still A Few Weeks Away
 

Keywords :   


Orexigen: Contrave Sales Dip, Passing Belviq Still A Few Weeks Away

2015-06-02 19:17:14| Biotech - Topix.net

Many Orexigen investors thought that this may be the week when Contrave outpaced Arena's Belviq in overall sales, but alas, the sales actually lost a bit of ground and that event is likely two or three weeks away. Contrave sales came in at a bit below 13,400 according to IMS health, and Contrave sits about 900 scripts behind the market share leader in Belviq.

Tags: sales away weeks passing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07Hurricane Beryl Graphics
02.07Hurricane Beryl Forecast Discussion Number 15
02.07Hurricane Beryl Wind Speed Probabilities Number 15
02.07Hurricane Beryl Forecast Advisory Number 15
02.07Hurricane Beryl Public Advisory Number 15
02.07Summary for Hurricane Beryl (AT2/AL022024)
02.07Levelling up: Can the next government help the UK games industry?
02.07Cheap TVs ahead of Euros help slow price inflation
More »